Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Kymera Therapeutics is a biotechnology business based in the US. Kymera Therapeutics stocks (KYMR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $49.66 – a decrease of 8.63% over the previous week. Kymera Therapeutics employs 143 staff and has a trailing 12-month revenue of around $72.8 million.
Finder's Pick for
Beginners
Finder's Pick for
Free Trades
Finder's Pick for
Commodity Stocks
Finder's Pick for
Global Trading
| Latest market close | $14.18 |
|---|---|
| 52-week range | $14.76 - $69.12 |
| 50-day moving average | $33.35 |
| 200-day moving average | $48.86 |
| Wall St. target price | $68.25 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.09 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $14.18 from 2022-05-24
| 1 week (2022-05-19) | -4.77% |
|---|---|
| 1 month (2022-04-26) | -57.11% |
| 3 months (2022-02-25) | -64.61% |
| 6 months (2021-11-26) | -73.64% |
| 1 year (2021-05-26) | -69.15% |
|---|---|
| 2 years (2020-05-22) | N/A |
| 3 years (2019-05-22) | N/A |
| 5 years (2017-05-22) | N/A |
| Revenue TTM | $72.8 million |
|---|---|
| Gross profit TTM | $-64,185,000 |
| Return on assets TTM | -11.5% |
| Return on equity TTM | -26.96% |
| Profit margin | -137.6% |
| Book value | $8.93 |
| Market capitalisation | $802.8 million |
TTM: trailing 12 months
We're not expecting Kymera Therapeutics to pay a dividend over the next 12 months.
Kymera Therapeutics, Inc. , a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. .
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.
Read more…iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of online gaming stocks.
Steps to owning and managing ENT stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KAMBI stock, with 24-hour and historical pricing before you buy.
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Steps to owning and managing RSI stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTHF stock, with 24-hour and historical pricing before you buy.
Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
Everything we know about the ProFrac Holding Corp IPO, plus information on how to buy in.
